22.77
+2.48%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanjing Vazyme Biotech Co
Its shares trade on Shanghai under the ticker 688105.SS. It has been listed since 15 November 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.38bn and a net loss of CN¥17.0m. At that date it held total assets of CN¥5.03bn and shareholders' equity of CN¥3.80bn.
Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Nov 2021
- Employees
- 4,096
- Website
- vazyme.com ↗
Leadership
Pay as last reported
- Mr. Lin CaoChairman of the Board, General Manager, since 2020CN¥729,900
- Mr. Wenxin BiChief Financial OfficerCN¥745,600
- Ms. Xiaomei HuDeputy General Manager, Director, since 2020CN¥909,200
- Mr. Lijun ZhangDeputy General Manager, Director, since 2020CN¥673,300
- Mr. Xiaoyu XuDeputy General ManagerCN¥670,200
- Mr. Su FengGeneral Manager of the Institute of Basic SciencesCN¥949,400
- Mr. Junwei NieGeneral Manager of Life Sciences DivisionCN¥1.3m
- Mr. Jin HuangSecretary of the BoardCN¥659,000
- Mr. Miao ChenDirector
- Mr. Bo TangDirectorCN¥669,300
- Ms. Leidi ZhangDirector
- Mr. Jiangnan CaiIndependent DirectorCN¥150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 87
- Social
- 79
- Governance
- 22
- Energy emissions (scope 2)
- 13,130.3 t
- Women in the workforce
- 56.01674%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nanjing Vazyme Biotech employs 4,096 full-time staff members for its operations.
- The company produces functional proteins like enzymes and antigens for research.
- PCR and gene sequencing series products are key offerings from the firm.
Weaknesses
- The company went public on 15 November 2021, limiting its market history.
- Nanjing Vazyme Biotech is headquartered in Nanjing, Jiangsu, which may limit reach.
- The firm focuses on antibody drugs, potentially narrowing its immediate product scope.
Opportunities
- Quantum dot immunofluorescence reagents offer new avenues for advanced diagnostic development.
- Latex enhanced immune turbidity reagents can expand the company's diagnostic portfolio.
- Colloidal gold immunochromatography reagents support growth in point-of-care testing markets.
Threats
- Biotechnology sector competition may pressure pricing for polymer organic materials.
- Regulatory changes could impact the production of biological reagent products.
- Market shifts might reduce demand for reverse transcription diagnostic instruments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.